Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xtant Medical Holdings (XTNT) reported third-quarter 2026 revenue of $24.3 million and announced an ongoing board-led review of strategic alternatives. Revenue fell from $33.3 million a year earlier but rose 5% sequentially. The company attributed the annual decline primarily to divestitures and absent wound care licensing revenue. Biologics revenue rose 13% year over year to $19.3 million, including $2.2 million from HEMOBLAST.
Gross margin fell to 56.3% from 66.1%. Net loss was $3.6 million, or $0.03 per share, versus $1.3 million in prior-year profit. Xtant no longer expects to meet its previous full-year guidance and is not issuing revised guidance during the review. At September 30, cash was $7.8 million and debt was $22 million. The company expects cash and revolving credit availability to fund at least the next 12 months under its current operating plan. The review has no completion timetable.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointBiologics revenue reached $19.3 million, up 13% year over year and 11% sequentially in Q3 2026.
- Moderate pointGeneral and administrative expenses fell to $5.0 million in Q3 2026 from $7.1 million a year earlier.
- Moderate pointTotal indebtedness declined to $22 million at September 30, 2026, from $25.4 million at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Xtant expects cash and revolving credit availability to fund operations for at least the next 12 months.
- Minor pointHEMOBLAST sales contributed $2.2 million to third-quarter 2026 revenue.
4 minor points
- Minor pointNon-GAAP biologics product revenue excluding HEMOBLAST and wound-reimbursement-affected products grew 8% sequentially and 6% annually in Q3.
- Minor pointSales and marketing expenses fell to $11.2 million in Q3 2026 from $11.7 million a year earlier.
- Minor pointResearch and development expenses fell to $496,000 in Q3 2026 from $634,000 a year earlier.
- Minor pointInterest expense fell to $590,000 in Q3 2026 from $904,000 a year earlier.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Xtant no longer expects to achieve its previous full-year 2026 guidance after two consecutive quarterly guidance misses.
- Moderate pointQ3 2026 revenue fell to $24.3 million from $33.3 million annually, despite rising 5% sequentially.
- Moderate pointQ3 gross margin fell to 56.3% from 66.1%, reflecting lost licensing revenue and sales mix.
- Moderate pointQ3 2026 net loss was $3.6 million, or $0.03 per share, versus $1.3 million profit a year earlier.
- Moderate pointQ3 adjusted EBITDA, adjusted earnings before interest, taxes, depreciation and amortization, was negative $1.5 million versus positive $4.5 million annually.
- Moderate pointCash declined to $7.8 million at September 30, 2026, from $17.1 million at December 31, 2025.
- Moderate pointA distribution agreement deposit write-off added $5 million to expenses in the first nine months of 2026. 13% of market cap
3 minor points
- Minor pointRevolving credit availability declined to $2.1 million at September 30, 2026, from $3.8 million at year-end 2025.
- Minor pointNine-month revenue fell to $68.200 million in 2026 from $101.570 million a year earlier.
- Minor pointNine-month net loss was $16.064 million in 2026 versus $4.916 million profit a year earlier.
News Explained
The release lists
Details
Market move: XTNT -4.20% vs previous close. Q3 2026 earnings report
On Nov 16, the day this news came out, the latest delayed price for XTNT is 4.20% below the previous close. The latest delayed price is $0.26.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Total revenue
- $24.3 million
- Q3 2026; compared with $33.3 million in Q3 2025 and $23.0 million in Q2 2026
- Biologics revenue
- $19.3 million; up 13% year over year and 11% quarter over quarter
- Q3 2026
- Gross margin
- 56.3%
- Q3 2026, compared with 66.1% in Q3 2025
- Net loss
- $3.6 million
- Q3 2026, compared with net income of $1.3 million in Q3 2025
- Adjusted EBITDA
- $1.5 million loss
- Q3 2026, compared with adjusted EBITDA of $4.5 million in Q3 2025
- Cash and cash equivalents
- $7.8 million
- As of September 30, 2026
- Total indebtedness
- $22 million
- As of September 30, 2026
- Operating funding outlook
- At least 12 months
- Company expects cash and revolving credit availability to fund operations under its current operating plan
Previous Earnings Reports
-
Revenue fell to $23.0 million and the company lowered 2026 revenue guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
non-gaap financial
revolving credit facility financial
gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives.
Third Quarter 2026 Financial Highlights
- Total revenue was
for the third quarter of 2026, compared to$24.3 million for the third quarter of 2025 and up$33.3 million 5% from in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of revenue from divested businesses and wound care licensing revenue.$23.0 million - Biologics revenue was
for the third quarter of 2026, up$19.3 million 13% from the third quarter of 2025 and up11% from the second quarter of 2026, third quarter 2026 revenue includes from sales of HEMOBLAST® Bellows.$2.2 million
"The Board is disappointed with Xtant's financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable," said Stavros Vizirgianakis, Chairman of the Board. "Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board's interests are directly aligned with stockholders. The Board's priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year."
The Board's active strategic review process is evaluating a broad range of potential actions to maximize stockholder value, which may include, among other things, operational and performance improvement initiatives, capital allocation and capital structure alternatives, commercial or strategic partnerships, restructurings, financings, acquisitions, dispositions, business combinations or other transactions. The Board has not set a timetable for completion of the strategic review process, and there can be no assurance that the process will result in any particular action or outcome. The Company does not intend to disclose further developments unless and until the Board approves a specific action or otherwise determines that further disclosure is appropriate or required.
Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was
Gross margin for the third quarter of 2026 was
Operating expenses for the third quarter of 2026 were
Net loss for the third quarter of 2026 was
Adjusted EBITDA, a non-GAAP measure, was a loss of
The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/ acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) is included in the financial tables at the end of this release.
As of September 30, 2026, the Company had
Based on its current operating plan, the Company expects its cash and cash equivalents, and availability under its revolving credit facility, to be sufficient to fund operations for at least the next 12 months.
2026 Financial Guidance
Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. While the Board of Directors conducts its strategic review process, the Company is not providing revised full-year 2026 financial guidance. At the same time, as detailed elsewhere in this release, the Board is encouraged by the recent momentum in the Company's core biologics business and remains committed to scaling this franchise throughout the strategic review process.
Conference Call
Xtant Medical will not host a conference call or webcast to discuss its third quarter 2026 financial results.
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in
Non-GAAP Financial Measures
To supplement the Company's consolidated financial statements prepared in accordance with
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," "expects," "anticipates," "plans," "believes," "estimates," "projects," "seeks," "aims," "goal," "strategy," "continue," "future," "will," "would," "should," "could," "may," "potential," "opportunity," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include, among others, statements regarding the recent momentum in the Company's core biologics products business and the Board's commitment to scaling that business; the Board's priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; the scope, timing, conduct and potential outcomes of the strategic review process; the Company's expectation that it will not achieve its previously issued full-year 2026 guidance; the Company's expectation that its cash and cash equivalents and availability under its revolving credit facility, will be sufficient to fund operations for at least the next 12 months; and the expected timing of the filing of the Company's Quarterly Report on Form 10-Q. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results, financial performance and need for additional capital; the Company's ability to sustain or increase revenue growth in its biologics business, including the possibility that recent growth trends will not continue; results of the Board's strategic review process, including the possibility that the process will not result in any strategic alternative, operational change, restructuring, transaction, initiative or other action, or that any action taken will not achieve its anticipated benefits or enhance stockholder value; the timing of the strategic review process and the possibility that it may be suspended, modified or terminated at any time; the Company's ability to identify, negotiate, finance, obtain any required approvals for and complete any strategic alternative, operational change, transaction, partnership, restructuring or other action on favorable terms or at all, and to implement successfully its strategic priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; risks associated with the strategic review process, including disruption and distraction of management, costs, and effects on employees, agents, customers, suppliers and other business relationships; the absence of financial guidance and the Company's inability to achieve its previously issued guidance; the Company's ability to generate operating cash flows and maintain availability under its revolving credit facility; the success of the Dilon distribution arrangement and the HEMOBLAST product and the possibility that the distribution agreement may be terminated and the effect of any such termination on the Company, its business and operating results; the ability of Dilon to continue to manufacture and supply the HEMOBLAST product and the effect of any such non-performance on the Company and its business and operating results; the success of the Company's expanded field sales force to improve its reach and leverage its contract portfolio and independent agent network; other risks associated with acquisitions and dispositions; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products, including the absence of future license revenue resulting from changes in the reimbursement environment; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject, including any litigation relating to the strategic review process; the effect of product recalls and defects; its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt and comply with the covenants in its credit agreements, including the minimum liquidity and net revenue covenants, to obtain any needed future amendments or waivers, and to access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 to be filed with the SEC on or about November 16, 2026. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
|
XTANT MEDICAL HOLDINGS, INC. Consolidated Balance Sheets (In thousands, except number of shares and par value) |
||||||||
|
|
||||||||
|
|
|
As of |
|
|
As of December 31, 2025 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
7,793 |
|
|
$ |
17,053 |
|
|
Restricted cash |
|
|
92 |
|
|
|
275 |
|
|
Trade accounts receivable, net of allowance for credit losses and |
|
|
18,823 |
|
|
|
17,803 |
|
|
Inventories |
|
|
32,503 |
|
|
|
30,263 |
|
|
Note receivable |
|
|
— |
|
|
|
10,462 |
|
|
Prepaid and other current assets |
|
|
1,395 |
|
|
|
2,389 |
|
|
Total current assets |
|
|
60,606 |
|
|
|
78,245 |
|
|
Property and equipment, net |
|
|
5,449 |
|
|
|
6,202 |
|
|
Right-of-use asset, net |
|
|
2,738 |
|
|
|
3,192 |
|
|
Goodwill |
|
|
6,074 |
|
|
|
6,074 |
|
|
Intangible assets, net |
|
|
229 |
|
|
|
299 |
|
|
Other assets |
|
|
127 |
|
|
|
133 |
|
|
Total Assets |
|
$ |
75,223 |
|
|
$ |
94,145 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES & STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
5,364 |
|
|
$ |
3,844 |
|
|
Accrued liabilities |
|
|
7,699 |
|
|
|
10,626 |
|
|
Current portion of long-term debt |
|
|
4,770 |
|
|
|
3,500 |
|
|
Current portion of lease liability |
|
|
588 |
|
|
|
622 |
|
|
Current portion of finance lease obligations |
|
|
19 |
|
|
|
35 |
|
|
Line of credit |
|
|
11,833 |
|
|
|
10,857 |
|
|
Total current liabilities |
|
|
30,273 |
|
|
|
29,484 |
|
|
Long-term Liabilities: |
|
|
|
|
|
|
|
|
|
Lease liability, less current portion |
|
|
2,248 |
|
|
|
2,665 |
|
|
Finance lease obligation, less current portion |
|
|
— |
|
|
|
12 |
|
|
Long-term debt, plus premium and less issuance costs |
|
|
5,436 |
|
|
|
11,026 |
|
|
Other liabilities |
|
|
7 |
|
|
|
5 |
|
|
Total Liabilities |
|
|
37,964 |
|
|
|
43,192 |
|
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
|
Stockholders' Equity: |
|
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
— |
|
|
|
— |
|
|
Common stock, |
|
|
— |
|
|
|
— |
|
|
Additional paid-in capital |
|
|
307,810 |
|
|
|
305,439 |
|
|
Accumulated other comprehensive loss |
|
|
(1) |
|
|
|
— |
|
|
Accumulated deficit |
|
|
(270,550) |
|
|
|
(254,486) |
|
|
Total Stockholders' Equity |
|
|
37,259 |
|
|
|
50,953 |
|
|
Total Liabilities & Stockholders' Equity |
|
$ |
75,223 |
|
|
$ |
94,145 |
|
|
XTANT MEDICAL HOLDINGS, INC. Consolidated Statements of Operations (Unaudited, in thousands, except number of shares and per share amounts) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue |
|
$ |
24,285 |
|
|
$ |
27,772 |
|
|
$ |
68,200 |
|
|
$ |
87,492 |
|
|
License revenue |
|
|
— |
|
|
|
5,483 |
|
|
|
— |
|
|
|
14,078 |
|
|
Total Revenue |
|
|
24,285 |
|
|
|
33,255 |
|
|
|
68,200 |
|
|
|
101,570 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Sales |
|
|
10,623 |
|
|
|
11,263 |
|
|
|
29,237 |
|
|
|
35,051 |
|
|
Gross Profit |
|
|
13,662 |
|
|
|
21,992 |
|
|
|
38,963 |
|
|
|
66,519 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
|
5,013 |
|
|
|
7,071 |
|
|
|
17,722 |
|
|
|
22,082 |
|
|
Sales and marketing |
|
|
11,181 |
|
|
|
11,746 |
|
|
|
29,735 |
|
|
|
34,566 |
|
|
Research and development |
|
|
496 |
|
|
|
634 |
|
|
|
1,626 |
|
|
|
1,643 |
|
|
Write-off of distribution agreement deposit |
|
|
— |
|
|
|
— |
|
|
|
5,000 |
|
|
|
— |
|
|
Total Operating Expenses |
|
|
16,690 |
|
|
|
19,451 |
|
|
|
54,083 |
|
|
|
58,291 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) Income from Operations |
|
|
(3,028) |
|
|
|
2,541 |
|
|
|
(15,120) |
|
|
|
8,228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(590) |
|
|
|
(904) |
|
|
|
(1,731) |
|
|
|
(2,953) |
|
|
Interest income |
|
|
— |
|
|
|
— |
|
|
|
220 |
|
|
|
— |
|
|
Unrealized foreign currency transaction |
|
|
(10) |
|
|
|
(56) |
|
|
|
12 |
|
|
|
146 |
|
|
Other income (expense) |
|
|
231 |
|
|
|
(16) |
|
|
|
820 |
|
|
|
(18) |
|
|
Total Other Expense |
|
|
(369) |
|
|
|
(976) |
|
|
|
(679) |
|
|
|
(2,825) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (Loss) Income from Operations |
|
|
(3,397) |
|
|
|
1,565 |
|
|
|
(15,799) |
|
|
|
5,403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for Income Taxes Current and |
|
|
(165) |
|
|
|
(257) |
|
|
|
(265) |
|
|
|
(487) |
|
|
Net (Loss) Income |
|
$ |
(3,562) |
|
|
$ |
1,308 |
|
|
$ |
(16,064) |
|
|
$ |
4,916 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (Loss) Income Per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.03) |
|
|
$ |
0.01 |
|
|
$ |
(0.11) |
|
|
$ |
0.04 |
|
|
Diluted |
|
$ |
(0.03) |
|
|
$ |
0.01 |
|
|
$ |
(0.11) |
|
|
$ |
0.03 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in the computation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
140,363,595 |
|
|
|
139,712,969 |
|
|
|
140,228,117 |
|
|
|
139,366,489 |
|
|
Diluted |
|
|
140,363,595 |
|
|
|
150,377,234 |
|
|
|
140,228,117 |
|
|
|
149,912,292 |
|
|
XTANT MEDICAL HOLDINGS, INC. Consolidated Statements of Cash Flows (Unaudited, in thousands) |
||||||||
|
|
||||||||
|
|
|
Nine Months Ended |
|
|||||
|
|
|
2026 |
|
|
2025 |
|
||
|
Operating activities: |
|
|
|
|
|
|
|
|
|
Net (loss) income |
|
$ |
(16,064) |
|
|
$ |
4,916 |
|
|
Adjustments to reconcile net (loss) income to net cash (used in) provided by |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
1,525 |
|
|
|
3,404 |
|
|
Loss (gain) on sale of fixed assets |
|
|
— |
|
|
|
(16) |
|
|
Non-cash interest |
|
|
380 |
|
|
|
415 |
|
|
Stock-based compensation |
|
|
2,451 |
|
|
|
2,165 |
|
|
Provision for reserve on accounts receivable |
|
|
987 |
|
|
|
568 |
|
|
Provision for excess and obsolete inventory |
|
|
2,904 |
|
|
|
1,318 |
|
|
Write-off of distribution agreement deposit |
|
|
5,000 |
|
|
|
— |
|
|
Other |
|
|
4 |
|
|
|
68 |
|
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(2,007) |
|
|
|
(5,639) |
|
|
Inventories |
|
|
(4,215) |
|
|
|
(2,789) |
|
|
Prepaid and other assets |
|
|
166 |
|
|
|
314 |
|
|
Accounts payable |
|
|
1,519 |
|
|
|
(1,279) |
|
|
Accrued liabilities |
|
|
(2,927) |
|
|
|
3,721 |
|
|
Net cash (used in) provided by operating activities |
|
|
(10,277) |
|
|
|
7,166 |
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(830) |
|
|
|
(1,987) |
|
|
Proceeds from sale of fixed assets |
|
|
129 |
|
|
|
206 |
|
|
Distribution agreement deposit |
|
|
(5,000) |
|
|
|
— |
|
|
Proceeds from divestitures |
|
|
10,368 |
|
|
|
5,000 |
|
|
Net cash provided by investing activities |
|
|
4,667 |
|
|
|
3,219 |
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
|
Borrowings on line of credit |
|
|
51,879 |
|
|
|
77,573 |
|
|
Repayments on line of credit |
|
|
(50,902) |
|
|
|
(78,385) |
|
|
Payments on long-term debt |
|
|
(4,701) |
|
|
|
(5,000) |
|
|
Debt issuance costs |
|
|
— |
|
|
|
(49) |
|
|
Payments on financing leases |
|
|
(27) |
|
|
|
(51) |
|
|
Payment of taxes from withholding of common stock on settlement of restricted |
|
|
(80) |
|
|
|
(116) |
|
|
Net cash used in financing activities |
|
|
(3,831) |
|
|
|
(6,028) |
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents and restricted cash |
|
|
(2) |
|
|
|
63 |
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents and restricted cash |
|
|
(9,443) |
|
|
|
4,420 |
|
|
Cash and cash equivalents and restricted cash at beginning of period |
|
|
17,328 |
|
|
|
6,221 |
|
|
Cash and cash equivalents and restricted cash at end of period |
|
$ |
7,885 |
|
|
$ |
10,641 |
|
|
Reconciliation of cash and cash equivalents and restricted cash reported in the |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
7,793 |
|
|
$ |
10,400 |
|
|
Restricted cash |
|
|
92 |
|
|
|
241 |
|
|
Total cash and restricted cash reported in condensed consolidated balance sheets |
|
$ |
7,885 |
|
|
$ |
10,641 |
|
|
XTANT MEDICAL HOLDINGS, INC. CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA (in thousands) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (Loss) Income |
|
$ |
(3,562) |
|
|
$ |
1,308 |
|
|
$ |
(16,064) |
|
|
$ |
4,916 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
483 |
|
|
|
1,161 |
|
|
|
1,525 |
|
|
|
3,404 |
|
|
Interest expense, net |
|
|
590 |
|
|
|
904 |
|
|
|
1,511 |
|
|
|
2,953 |
|
|
Tax expense |
|
|
165 |
|
|
|
257 |
|
|
|
265 |
|
|
|
487 |
|
|
Non-GAAP EBITDA |
|
|
(2,324) |
|
|
|
3,630 |
|
|
|
(12,763) |
|
|
|
11,760 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (Loss) Income/Total Revenue |
|
|
(14.7) |
% |
|
|
3.9 |
% |
|
|
(23.6) |
% |
|
|
4.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP EBITDA/Total Revenue |
|
|
(9.6) |
% |
|
|
10.9 |
% |
|
|
(18.7) |
% |
|
|
11.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON-GAAP ADJUSTED EBITDA CALCULATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash compensation |
|
|
830 |
|
|
|
641 |
|
|
|
2,451 |
|
|
|
2,165 |
|
|
Write-off of distribution agreement deposit |
|
|
— |
|
|
|
— |
|
|
|
5,000 |
|
|
|
— |
|
|
Divestiture/acquisition-related expenses |
|
|
(94) |
|
|
|
74 |
|
|
|
(612) |
|
|
|
369 |
|
|
Acquisition-related fair value adjustments |
|
|
37 |
|
|
|
140 |
|
|
|
132 |
|
|
|
311 |
|
|
Unrealized foreign currency translation loss (gain) |
|
|
10 |
|
|
|
56 |
|
|
|
(12) |
|
|
|
(146) |
|
|
Separation related expenses |
|
|
69 |
|
|
|
— |
|
|
|
69 |
|
|
|
23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjusted EBITDA |
|
$ |
(1,472) |
|
|
$ |
4,541 |
|
|
$ |
(5,735) |
|
|
$ |
14,482 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjusted EBITDA/Total |
|
|
(6.1) |
% |
|
|
13.7 |
% |
|
|
(8.4) |
% |
|
|
14.3 |
% |
|
XTANT MEDICAL HOLDINGS, INC. RECONCILIATION OF NON-GAAP BIOLOGICS PRODUCT REVENUE GROWTH (in thousands) |
||||||||||
|
|
||||||||||
|
|
|
Three Months Ended |
|
|
|
|||||
|
|
|
September 30, |
|
June 30, 2026 |
|
% Increase |
|
|||
|
Total Revenue |
|
$ |
24,285 |
|
$ |
23,031 |
|
|
|
|
|
License Revenue |
|
|
— |
|
|
— |
|
|
|
|
|
Hardware Revenue |
|
|
4,944 |
|
|
5,671 |
|
|
|
|
|
Biologics Revenue |
|
|
19,341 |
|
|
17,360 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales related to HEMOBLAST and products affected by the |
|
|
2,204 |
|
|
1,518 |
|
|
|
|
|
Biologics product revenue excluding HEMOBLAST and |
|
$ |
17,137 |
|
$ |
15,842 |
|
|
8 |
% |
|
|
||||||||||
|
|
|
Three Months Ended |
|
|
|
|||||
|
|
|
September 30, |
|
September 30, |
|
% Increase |
|
|||
|
Total Revenue |
|
$ |
24,285 |
|
$ |
33,255 |
|
|
|
|
|
License Revenue |
|
|
— |
|
|
5,483 |
|
|
|
|
|
Hardware Revenue |
|
|
4,944 |
|
|
10,623 |
|
|
|
|
|
Biologics Revenue |
|
|
19,341 |
|
|
17,149 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales related to HEMOBLAST and products affected by the |
|
|
2,204 |
|
|
935 |
|
|
|
|
|
Biologics product revenue excluding HEMOBLAST and |
|
$ |
17,137 |
|
$ |
16,214 |
|
|
6 |
% |
View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-reports-third-quarter-2026-financial-results-and-announces-board-led-strategic-review-process-302939954.html
SOURCE Xtant Medical Holdings, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Xtant Medical's third-quarter 2026 earnings results?
Xtant reported $24.3 million in revenue and a $3.6 million net loss, or $0.03 per share. A year earlier, revenue was $33.3 million and net income was $1.3 million, or $0.01 per diluted share.
Why does Xtant no longer expect to meet its 2026 guidance?
Xtant cited year-to-date performance as the reason it no longer expects to achieve its previously issued full-year 2026 guidance. The company is not providing revised full-year guidance while the board conducts its strategic review.
What alternatives is Xtant Medical considering in its strategic review?
The board is evaluating operational improvements, capital allocation and capital structure alternatives, alongside partnerships, restructurings, financings, acquisitions, dispositions, business combinations and other transactions. Further developments will not be disclosed unless the board approves a specific action or determines that disclosure is appropriate or required.
How much did lost businesses and licensing revenue affect Xtant's third-quarter 2026 sales?
The annual comparison included the absence of $5.4 million in prior-year revenue from divested Coflex/CoFix assets and the international hardware business, plus $5.5 million in prior-year wound care licensing revenue. HEMOBLAST revenue of $2.2 million partially offset those effects.